The following stories appear in full on today's Vidyya Medical News Service Web site.
Researchers will convene at the National Institutes of Health (NIH) to discuss how to make the best uses of a new technology that allows researchers and physicians to make detailed, three-dimensional maps of the networks through which various parts of the brain communicate. The technology, devised by researchers at the National Institute of Child Health and Human Development (NICHD), also holds promise for providing similar detailed maps of the skeletal muscles, heart, and circulatory system.
For more information: New MRI Technology Provides Detailed Views Of Brain Development, Response To Injury
Diffusion Tensor Magnetic Resonance Imaging, or DT-MRI, is a technology that measures the random motion of hydrogen atoms within water molecules in all three dimensions, non-invasively, and in vivo. DT-MRI adds to conventional MRI the capability of measuring the random motion of water molecules, referred to as diffusion. Although water appears placid to the naked eye, individual water molecules are constantly in motion, colliding with each other and with other molecules in tissues at high speeds. Learn more about DT-MRI in today's issue.
For more information: About Diffusion Tensor Magnetic Resonance Imaging
Anxiety disorders are serious medical illnesses that affect approximately 19 million American adults. These disorders fill people's lives with overwhelming anxiety and fear. Unlike the relatively mild, brief anxiety caused by a stressful event such as a business presentation or a first date, anxiety disorders are chronic, relentless, and can grow progressively worse if not treated. Effective treatments for anxiety disorders are available, and research is yielding new, improved therapies that can help most people with anxiety disorders lead productive, fulfilling lives. Vidyya is pleased to present a newly revised edition of the National Institute For Mental Health's brochure about anxiety disorders.
For more information: Information For Patients: Anxiety
Researchers from the Arkansas Cancer Research Center, Mayo Clinic, and M.D. Anderson Cancer Center presented data at the 42nd annual meeting of the American Society of Hematology on clinical trials evaluating the safety and efficacy of Thalomid (thalidomide) as a single agent and in combination treatment for multiple myeloma. Studies presented included new clinical trial data on the use of Thalomid alone and Thalomid in combination with conventional therapies for treatment of patients with early stage multiple myeloma. In addition, clinical data presented was consistent with previously published results on the potential use of Thalomid in treating refractory multiple myeloma and included survival data of patients.
For more information: Clinical Trial Results On The Use Of Celgene's Thalomid®
A Mayo Clinic study published in the December issue of the American Journal of Psychiatry debunks the commonly held notion that about 15 percent of people diagnosed with depression will commit suicide. After analyzing 100 suicide studies conducted over the past 30 years, Mayo Clinic researchers concluded that a more accurate suicide rate for patients with depression is 2 to 9 percent.
For more information: Mayo Clinic Study Shows Suicide Rates Overstated In People With Depression
Today's Vidyya articles are:
As always, we hope you enjoy the issue.